About tirzepatide telehealth What is tirzepatide telehealth?
Tirzepatide telehealth is medical care delivered online: you complete a health questionnaire, a physician licensed in your state reviews it, and — when treatment is appropriate — tirzepatide is prescribed and shipped from a licensed pharmacy, with follow-up care handled by secure messaging instead of office visits. Tirzepatide itself is a once-weekly injection that activates two gut-hormone receptors, GIP and GLP-1, reducing appetite and slowing digestion; clinicians typically consider it for adults with a BMI of 30 or higher, or 27 with a weight-related condition. The brand-name versions Zepbound and Mounjaro are FDA-approved. Many telehealth providers prescribe compounded tirzepatide instead, which is not FDA-approved and is not therapeutically equivalent to Zepbound or Mounjaro.
In the SURMOUNT-1 trial, adults on the highest tirzepatide dose lost on average about 21% of their body weight over 72 weeks, versus 3% on placebo.1 (Trial results for the branded molecule; compounded tirzepatide is not FDA-approved or shown to be equivalent.)